A variety of albumin polymers were prepared and tested for binding with hepatitis B surface antigen (HBsAg): synthetic polymers cross-linked by either glutaraldehyde or carbodiimide; heat-aggregated polymers made by heating albumin solutions at 60°C for 10 h with or without albumin stabilizer; and polymers isolated from fresh or long-stored commercial therapeutic albumin solutions. A sensitive solid-phase, competitiveinhibition radioimmunoassay, which can detect as little as 10 ng of glutaraldehyde-cross-linked human albumin polymer (PHALB-G), was developed and used to measure binding. The binding of PHALB-G with HBsAg was 150-to 1,000-fold greater than that of any other albumin polymer. Glutaraldehyde-cross-linked bovine albumin polymer showed no binding. Albumin monomer and dimer fractions produced by glutaraldehyde treatment exhibited some binding, albeit much weaker than PHALB-G. As measured by a direct-binding assay with solid-phase PHALB-G, the attachment of HBsAg particles from sera positive for antibody to the e antigen was less efficient than that from sera positive for e antigen, even when all sera were tested at equal HBsAg concentrations. In protein blot experiments with radiolabeled albumin preparations, PHALB-G bound almost exclusively to HBsAg polypeptide P31 and showed no binding with the major polypeptides P23 and P26. None of the other radiolabeled albumin polymers was reactive. These results indicate that the interaction between PHALB-G and HBsAg is not due to polymerization of albumin per se, but rather is unique and site specific.
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Numerous investigators have reported that polymerized human albumin (PHALB) can bind to hepatitis B surface antigen (HBsAg) (6, 7, 15, 17, 18) . Some of these (6, 7, 15) also observed that the PHALB-HBsAg interaction was species specific and suggested that this specificity could explain the restricted host range of hepatitis B virus (HBV). Furthermore, receptors for PHALB have been reported to occur on hepatocytes (13, 28, 31) . PHALB has been postulated to be the mediator of hepatotropic infection by HBV (7; for review, see reference 29) .
All of these studies, however, used exclusively glutaraldehyde-cross-linked PHALB (PHALB-G). In the present work, albumin polymers were prepared by various methods, purified, and tested for reactivity toward HBsAg. In addition, a sensitive solid-phase competitive-inhibition radioimmunoassay (RIA) was developed so that the interaction between any albumin preparation and HBsAg could be quantitated. A polypeptide from purified HBsAg particles was found to bear a receptor for PHALB-G, but not for any other albumin polymer. of its inability to bind with HBsAg, PBALB-G was used as a negative control.
MATERIALS AND METHODS

Buffers
Polymerized human albumin prepared by carbodiimide cross-linking (PHALB-C). The NYBC albumin used to prepare PHALB-G was also treated with water-soluble carbodiimide by the following procedure: 500 mg of albumin was dissolved in 9 ml of 0.15 M NaCl, the pH was adjusted to 5.4 with 1 N HCI, and the volume was brought to 10 ml with 0.15 M NaCl. The solution was then stirred with 0.375 ml of 0.81 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl (Sigma) for 2 h at room temperature and subsequently dialyzed against 0.15 M NaCl for 17 h at 4°C. After dialysis, the solution was mixed with an additional 250 mg of human albumin for 30 min at room temperature and then chromatographed on 8% agarose as indicated above (see Fig. 3C ). Fractions 41 to 54 were pooled, concentrated by ultrafiltration, and dialyzed against PBS, pH 7.0. The a280 of this material (PHALB-C) was found to be 0.71.
Polymerized human albumin prepared by heating (PHALB-H). NYBC albumin was dissolved in 0.1 M sodium phosphate buffer, pH 7.0, to make a 5% solution and was heated for 10 h at 60°C under the conditions described previously (34) . After heating, the solution was chromatographed on 8% agarose; polymer (PHALB-H) was eluted in the first peak (see Fig. 3D ).
Polymerized human albumin isolated from fresh or longstored commercial therapeutic albumin solutions (PHALB-N). Samples of 25% normal serum albumin (human) (one lot from each of 13 manufacturers) and plasma protein fraction (human) (one lot from each of four manufacturers) were chromatographed individually on 8% agarose as indicated above. The fraction with the highest absorbance in the first peak was centrifuged at 73,000 x g for 24 h at 4°C to harvest the protein; the pellet was dissolved in PBS, pH 7.0. The mean a280 was determined to be 2.0. Samples were stored at -40°C until assayed for binding activity.
The long-stored albumin comprised two lots of normal serum albumin, both of which were formulated from the same batch of albumin. One was prepared as a 5% solution and stored at 32 to 37°C; the other was prepared as a 25% solution and stored at 5°C. After storage for 29 years, samples were chromatographed on 8% agarose. The fraction with the highest absorbance in the first peak was tested for binding with HBsAg.
HBsAg. Hepatitis B markers were determined by using commercial RIA kits from Abbott Laboratories (HBsAg by Ausria II; hepatitis B e antigen [HBeAg] and antibody [anti-HBe] by Abbott-HBe). For quantitation of HBsAg in sera, dilutions of serum samples were compared with those of a highly purified HBsAg standard (3) in a parallel line assay (25) . The purified HBsAg used in the protein blot experiments consisted of 20-nm spherical particles, which were isolated from an HBeAg-positive serum by gel filtration on Sepharose 4B (Pharmacia Fine Chemicals, Inc.) followed by affinity chromatography on an anti-HBs column and subsequently by rate-zonal centrifugation. The purity of this preparation was comparable to that of the highly purified HBsAg standard isolated by the established centrifugation procedure (3). An HBsAg-positive serum (see no. 1 in Table  3 ) with an HBsAg content of 25.5 ,ug/ml was used as the source of antigen in the competitive-inhibition RIA for polymerized albumin (see below). The dilutions were made with PBS containing 1% BSA and 0.02% NaN3, pH 7.4. Competitive-inhibition RIA. The competitive-inhibition RIA is analogous to the direct-binding assay described above and is performed under similar conditions. It is based on the assumption that any albumin polymer, oligomer, or monomer species capable of interacting with HBsAg should compete with solid-phase PHALB-G for binding to the HBsAg in the fluid phase. Therefore, 25 ptl of solutions containing PHALB-G or other albumin preparation was added to 25 RI of diluted HBsAg-positive serum in wells coated with PHALB-G. Subsequent steps were the same as those in the direct-binding assay. The counts per minute corresponding to HBsAg binding in the absence of any competing protein was expressed as 100%. In each experiment a linear standard curve was established by plotting percent binding against the quantity of competing (i.e., fluid-phase) PHALB-G on three-cycle LOGIT-LOG paper (see Fig. 2 ). The binding of HBsAg by the various albumin preparations was read from this curve and expressed in terms of the equivalent quantity of PHALB-G.
SDS-PAGE. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in gel tubes was performed essentially by the method of Weber and Osborn (32) ; that in slab gels was performed by the Laemmli procedure (9). When HBsAg polypeptides were to be separated, purified HBsAg was treated with 1% SDS-1% 2-mercaptoethanol-8 M urea in 0.0625 M Tris-chloride buffer, pH 7.2, for 30 min at 37°C before electrophoresis.
Protein blotting. After SDS-PAGE in slab gels, the HBsAg peptides were electrophoretically transferred to nitrocellulose membranes according to Towbin et al. (30) . The membranes were cut into strips and incubated with various 125I-labeled probes at an activity of 2.5 x 105 cpm/ml. The radiolabeled anti-HBs was that supplied with the Ausria II kit. PHALB-G and other albumin preparations were labeled with carrier-free Na125I (New England Nuclear Corp.) by the chloramine-T procedure; their specific activities were between 89 and 99 Bq/ng (24 to 27 Ci/g). Binding patterns were revealed by autoradiography. The protein patterns were identified by staining the gels with Coomassie blue.
Protein purity. Purity was assessed by means of SDS-PAGE in gel tubes (5% acrylamide gels), CAE, and highpressure liquid chromatography. The latter two procedures have been described elsewhere (34) .
Protein concentration. Protein concentration was determined initially by using Bio-Rad protein assay reagent according to the procedure of Bradford (1) . Bovine albumin 738 YU, FINLAYSON, AND SHIH (crystallized and lyophilized; Sigma) quantitated by UV spectrophotometry (a280 0.66) was used as a standard for the assays. Concomitant measurements by this procedure and UV spectrophotometry were used to determine a280 for each type of polymer studied. After these values were established, protein concentrations were measured by UV spectrophotometry.
RESULTS
Direct binding: concentration effects and specificity. The binding of HBsAg to solid-phase PHALB-G increased as increasing concentrations of the latter were used for coating the microtiter plates, up to a concentration of approximately 60 ,ug/ml (Fig. 1) . Increased binding was also observed as the concentration of the HBsAg-positive serum was raised from a dilution of 1:1,000 (corresponding to 25.5 ng of HBsAg per ml) to 1:50. Therefore, in subsequent studies, the PHALB-G concentration used for coating was 60 j,g/ml and the concentration of HBsAg was between 1:400 and 1:200.
Specificity of the binding was demonstrated in two ways. First, an HBsAg-negative serum showed no binding, regardless of the concentration of PHALB-G used for coating (Fig.  1) . Second, PBALB-G exhibited negligible binding with HBsAg (<2% that of PHALB-G under the same conditions) and showed no increase when the concentration used for coating was raised.
Solid-phase competitive-inhibition RIA. To quantitate the interaction between HBsAg and the various albumin preparations, a sensitive competitive-inhibition RIA was developed. A linear standard curve was obtained when the percent binding was plotted against the quantity of competing (fluid-phase) PHALB-G on LOGIT-LOG paper (Fig. 2) . As little as 10 ng of PHALB-G could be detected. In the presence of 300 ng of PHALB-G, the binding was 90% inhibited.
Various albumin preparations: characteristics and binding to HBsAg. Chromatography of non-cross-linked human albumin on 8% agarose revealed no breakthrough peak, small amounts of oligomer and dimer, and a large peak of albumin monomer (Fig. 3A) . When individual fractions were tested by the competitive-inhibition RIA, they exhibited little or no binding to HBsAg.
The elution profile of glutaraldehyde-cross-linked human albumin included a large breakthrough peak, some oligomer and dimer, and a large albumin monomer peak (Fig. 3B) . The monomer and dimer peaks arose primarily from the noncross-linked albumin added to quench the cross-linking reaction. When fractions were assayed for HBsAg binding, most of the activity was found in the breakthrough peak. Glutaraldehyde-cross-linked oligomers also bound HBsAg, albeit to a lesser extent, whereas glutaraldehyde-treated dimer and monomer were considerably less reactive.
The high molecular weight of glutaraldehyde-cross-linked polymer was confirmed in several systems. The Bio-Gel A-1.5m columns were calibrated with molecular weight markers. Under these chromatographic conditions, the peak of the thyroglobulin marker (molecular weight 669,000) was located in fractions 51 to 52. Hence PHALB-G is at least a decameric albumin, if its conformation is similar to that of the marker. The pooled PHALB-G (fractions 41 to 54) was eluted as a breakthrough peak when subjected to high-pressure liquid chromatography on a TSK 3000 SW column. Similarly, during SDS-PAGE, PHALB-G was unable to penetrate a 5% acrylamide gel, irrespective of whether the protein was treated with 2-mercaptoethanol. In CAE exper- iments PHALB-G migrated as a single band. Its anodal migration at pH 8.6 was greater than that of non-cross-linked albumin monomer, indicating that the cross-linking had increased its net negative charge. This behavior is consistent with the known reactivity of glutaraldehyde toward the e-amino groups of lysine residues (5).
When the preparation obtained by cross-linking human albumin with carbodiimide was chromatographed on 8% agarose, a large breakthrough peak was observed (Fig. 3C) . However, none of the fractions in this peak or any other fractions in the chromatogram showed significant binding to HBsAg in either the direct-binding or the competitiveinhibition RIA. This lack of reactivity was confirmed even when a concentration of PHALB-C as high as 0.8 mg/ml was used for direct coating and 6.3 mg/ml was used for competitive-inhibition RIA. During CAE, PHALB-C remained close to the origin, suggesting that it bears a relatively low net charge under the conditions used in the binding assays.
Heating non-cross-linked human albumin at 60°C for 10 h in the absence of stabilizers produced a large breakthrough peak, but no binding activity was detected in any of the fractions tested (Fig. 3D) . The protein in the breakthrough peak migrated as a-globulin during CAE. The relative HBsAg-binding activities of the albumin in various individual chromatographic fractions are summarized in Table 1 . The binding of PHALB-G to HBsAg (measured in terms of grams of protein bound per gram of total protein) was far greater than that of any other fraction. Binding by glutaraldehyde-treated dimer or monomer was much weaker, and that of the other species appeared to be negligible. In each well, 25 ,ul of the HBsAg-positive serum (1:400 dilution) was incubated with 25 ,ul of competing PHALB-G at decreasing concentrations (two-fold serial dilutions) or with 25 p.l of another competing albumin preparation. HBsAg bound to solid-phase PHALB-G was detected by incubating with radiolabeled anti-HBs. When the buffer (PBS-1% BSA-0.02% NaN3, pH 7.4) was incubated in the absence of HBsAg, it gave 106 + 18 cpm (mean + standard deviation). The counts per minute corresponding to the HBsAg bound in the absence of any competing albumin (2,055 + 96 cpm) was designated as 100%. Each point represents the mean of triplicate determinations.
To determine whether the albumin polymer present in commercial therapeutic solutions of human albumin can interact with HBsAg, polymer was prepared either by isolating it from fresh therapeutic albumin products or by heating non-cross-linked human albumin under conditions resembling those used in commercial manufacturing (i.e., 60°C for 10 h). Unlike the commercial process, these heating experiments utilized suboptimal stabilizer concentrations so as to increase the amount of polymer formed (34) . The HBsAg-binding activities of these albumin polymers (PHALB-N and PHALB-H, respectively) were compared with those of the chemically modified preparations by competitive-inhibition RIA. None of these polymers appeared to bind HBsAg significantly (Table 2) .
Because polymers are formed during storage of therapeutic albumin solutions (2), two long-stored samples were also used as sources of PHALB-N. The PHALB-N prepared from commercial albumin stored as a 5% solution at 32 to 37°C showed negligible interaction with HBsAg. That isolated from albumin stored as a 25% solution at 5°C for 29 years (nearly six times the shelf life at this temperature) gave some evidence of HBsAg binding, but it was less than 0.7% that of PHALB-G ( Table 2 ). The binding of PHALB-G with HBsAg was thus 150-to 1,000-fold greater than that of any other PHALB studied. As in the direct-binding assay, PBALB-G showed no binding in the competitive-inhibition RIA (Table 2 ). These results suggest that the binding of HBsAg is highly specific for sites produced by the interaction of human albumin and glutaraldehyde.
Site of interaction between PHALB-G and HBsAg. Recently Machida et al. (14) used 125I-labeled anti-HBs to identify a receptor for PHALB-G on an HBsAg polypeptide (P31) with a molecular weight of 31,000. However, because anti-HBs preferentially detects the minor, immunodominant polypeptide P31 and shows relatively less attraction to the major polypeptides P23 and P26 (16), it seemed possible that this identification was influenced by the experimental design. Therefore, our approach was to use 125I-labeled albumin polymer to locate the binding site(s) on HBsAg particles. Purified HBsAg was solubilized under reducing conditions, and its polypeptides were separated by SDS-PAGE. These polypeptides were transferred to nitrocellulose membranes and incubated with various 125I-labeled albumin preparations. The minor polypeptide P31 became strongly radioactive when '25I-labeled PHALB-G was used as the probe, but no radioactivity appeared in the position of polypeptide P23 or P26 (Fig. 4, lane A) . Two minor radioactive bands were also detected: one migrated at a region corresponding to a molecular weight of 35,000; the other, at about 90,000. The former is probably the glycosylated form of P31 (14) . Radioiodinated non-cross-linked human albumin and PHALB-C produced no radioactive bands (Fig. 4, lanes B and C); neither did 125I-labeled PBALB-G (not shown).
These results agree well with those of Machida et al. (14) and VOL. Fig. 3 except that fraction 67 was used to represent the dimer shown in Fig. 3D .
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suggest that P31 contains a specific site at which HBsAg binds tightly to PHALB-G but weakly, if at all, to other 20 types of albumin polymers.
Correlation between HBsAg-binding and HBeAg. Imai et al. (7) positive for HBeAg or anti-HBe (Table 3) 
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Although numerous studies have dealt with the interrelationship among HBsAg, hepatocytes, and polymerized albu- 40 min, the nature of this relationship and its pathophysiological significance remain unclear. For example, it has been 20 suggested that albumin polymer produced by "aging" albumin in vitro shares an antigenic determinant(s) with that produced by glutaraldehyde treatment (12, 19, 21, 22) . By contrast, the present work demonstrates that albumin polymers formed by a variety of procedures (including long-term storage) bind HBsAg to a much lesser extent than does PHALB-G, if they bind at all. Furthermore, whereas albumin polymers can arise during isolation and storage of albumin (2) and have been reported to occur in the sera of patients with liver disease (12) , their presence in the circulation of normal individuals has not been established. In addition, the HBsAg-binding ability induced by treating albumin with glutaraldehyde is not dependent on polymerization per se, inasmuch as the albumin dimer (and, to a smaller degree, the monomeric albumin) produced by this treatment can bind to HBsAg.
Receptors for glutaraldehyde-cross-linked rabbit albumin polymer have been found on rabbit hepatocyte membranes (13) . However, a subsequent study showed that these receptors interact not only with the polymer but also with monomeric glutaraldehyde-modified rabbit albumin (20) . Such receptors for glutaraldehyde-treated albumin have also been demonstrated on human hepatocytes, but they are not specific for either the molecular size of the treated albumin or the species of the donor (28, 31) . The receptor site(s) on b These values were obtained by using a standard curve that spanned the range 100 ng to 10 pLg; for all others the range used was 10 ng to 1 ,ug (see Fig.   2 ).
cHuman albumin was heated (60°C, 10 h) with or without the stabilizer sodium caprylate (CA) or N-acetyltryptophan (AT); stabilizer concentration in stock solutions was verified by methods described previously (33) . The data represent the binding of the respective first peak fraction.
d Mean ± standard deviation for 17 preparations.
HBsAg, on the other hand, is highly species specific. It was found to react with glutaraldehyde-cross-linked albumin from humans (6, 7, 15, 27) and chimpanzees (7), but not from other animal species (7, 15) . Our efforts to locate the PHALB-G receptor on HBsAg utilized 1251-labeled PHALB-G as a probe and revealed that receptor activity was confined almost exclusively to polypeptide P31, albeit its glycosylated derivative, P35, was weakly radioactive (Fig. 4) (4, 8) , which does not express HBeAg. HBsAg polypeptide P31 is composed of polypeptide P23, which is encoded by the S gene of the HBV genome, and 55 additional amino acid residues at the amino terminus, which are encoded by the pre-S gene (14, 26) . Because PHALB-G binds to P31 but not to P23 (Fig. 4) , this 55-residue skein must bear the receptor, as concluded by Machida et al. (14) . A recent report (23) indicated that HBV which had undergone a mutation in the pre-S region failed to express polypeptide P35 and hence lost the receptor site for PHALB-G. Furthermore, Neurath et al. (16) presented evidence that immunodominant, disulfide bond-independent epitopes are located within the amino-terminal portion of this skein. A synthetic peptide consisting of the first 26 amino-terminal residues was prepared and was found to elicit antibodies (in rabbits) to the HBV envelope (16) . (The binding of this synthetic peptide to PHALB-G, however, was not tested.) These authors have suggested that the translational product of the pre-S gene may be involved in the attachment of HBV to cells, in which case peptide analogs corresponding to selected sequences (e.g., the 26-residue span) would be promising immunogens for protecting against infection (16) . Nonetheless, in view of the present findings, the role, if any, of polymerized albumin in this attachment remains to be elucidated.
